Survodutide

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Survodutide has no FDA marketing authorisation as of May 2026. Phase 3 SYNCHRONIZE-1 (obesity) results were announced April 2026; an NDA submission for obesity is anticipated. The compound holds FDA Breakthrough Therapy Designation for non-cirrhotic MASH. Supply and administration outside of registered clinical trials is not authorised.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Survodutide

Origin

29-amino-acid synthetic peptide derived from a glucagon scaffold, engineered by Boehringer Ingelheim and Zealand Pharma (development code BI 456906). Key structural modifications include replacement of three positions (18, 20, 23) with GLP-1–like residues, introduction of the novel unnatural amino acid Ac4c at position 2 to increase metabolic stability, and attachment of a C18 fatty-diacid via a linker at position 24 to extend plasma half-life and enable once-weekly dosing. CAS 2805997-46-8; MW ~4232 Da.

Registry IDs

PubChem CID

171378821

CAS

2805997-46-8

InChIKey

MEDXQFAHWBMVIM-PCLHIQTFSA-N

Molecular formula

C192H289N47O61

Molar mass

4232 g/mol

Monoisotopic

4229.0957042 Da

InChIKey

MEDXQFAHWBMVIM-PCLHIQTFSA-N

Appearance

White to off-white lyophilised powder (typical for long-chain fatty-acid–conjugated synthetic peptides of ~4.2 kDa)

Solubility

Soluble in aqueous buffers at physiological pH; the C18 fatty-diacid conjugation…

Sequence not available in current seed.

Stability: Extended plasma half-life conferred by reversible albumin binding via the C18 fatty-diacid linker; degradation pathways expected to include deamidation, methion

Vial sizes

null mg

Purity grades

research grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Survodutide simultaneously engages two distinct receptors: the glucagon-like peptide-1 receptor (GLP-1R), which mediates appetite suppression, slowing of gastric emptying, and incretin-dependent insulin secretion; and the glucagon receptor (GCGR), which increases hepatic fatty-acid oxidation, stimulates thermogenesis, and raises energy expenditure
• Co-agonism at both receptors produces complementary and additive reductions in body weight beyond what GLP-1 monoagonism alone achieves
• In the liver, GCGR engagement is hypothesised to reduce lipotoxicity by promoting direct hepatic lipolysis, providing a mechanistic rationale for studying survodutide in metabolic dysfunction-associated steatohepatitis (MASH)
• The fatty-diacid modification promotes reversible albumin binding, slowing renal clearance and extending the effective half-life without materially altering receptor-binding selectivity

Pharmacokinetics (ADME)

Half-life

Approximately 6–7 days (supports once-weekly subcutaneous dosing); steady-state plasma concentrations reached by approximately week 5

Clearance

Not fully characterised publicly; subcutaneous linear PK observed in phase 1 studies in healthy volunteers and subjects with obesity or liver impairment (NCT06352411, NCT05296733); albumin binding extends half-life via reduced renal filtration

PK–PD note: Phase 1 studies in subjects with renal impairment (NCT06352411) and hepatic impairment (NCT05296733) found no clinically meaningful alteration in exposure requiring dose adjustment; PK in cirrhosis wa…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Awad A, et al. Evaluating the efficacy and safety of survodutide for obesity: a systematic review and meta-analysis of randomized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(4):514-522. — PRISMA-registered systematic review/meta-analysis; 4 RCTs included; searched PubMed/Web of Science/Scopus/Cochrane through May 2024
• Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome. 2024;16(1):264. — Meta-analysis of RCTs reporting weight, BMI, waist circumference reductions
• Xiao, et al. Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis. Diabetes Obes Metab. 2025. — Systematic review/meta-analysis of glycemic control and weight loss outcomes
• Wharton S, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity. 2025;33(1):67-77. — Design paper for pivotal phase 3 program

5 registered trials — 1 currently recruiting.

Phase 1
NCT06352411
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

COMPLETED

Phase 1
NCT07413913
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

ACTIVE_NOT_RECRUITING

Phase 1
NCT06745284
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

ACTIVE_NOT_RECRUITING

Phase 1
NCT05296733
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

COMPLETED

Phase 1
NCT07407348
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

RECRUITING

Summary (literature)

Across Phase 1–3 clinical trials, the most frequently reported adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. In the Phase 2 obesity trial, GI disorders were reported by approximately 75% of survodutide-treated participants versus 42% on plac…

WADA status

Not specifically listed by name on the 2026 WADA Prohibited List. Because survodutide is a synthetic peptide that acts on metabolic hormone receptors, it may fa…

Dominant research route: Subcutaneous (SC)

Phase 1 (healthy volunteers and people with overweight/obesity), Phase 2 (type 2 diabetes, obesity, MASH/NASH), and Phase 3 (SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-CVOT) human trials; once-weekly injection; bioequivalence study comparing pre-filled syringe vs pre-filled pen formulations

Bioavailability: Subcutaneous survodutide exhibited linear pharmacokinetics in Phase 1 trials. Terminal half-life ~109–115 h (~6 days), enabling once-weekly dosing. High binding affinity for human serum albumin (>99%). Peak plasma concentrations achieved 60–96 hours after injection. Albumin-bound circulating drug provides a stable depot releasing over the dosing interval.

SC is the only route studied across all clinical trials. A bioequivalence trial (NCT referenced in AdisInsight 700390419) compared pre-filled syringe (Formulation A) vs pre-filled pen (Formulation B2) SC delivery. Doses studied range from 0.3 mg to 6.0 mg once weekly with titration. No IV, IM, IP, intranasal, or topical routes have been reported in clinical or preclinical literature.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $11.00 · median $15.10 · p75 $29.00 · 7 researched vendors

Legit, COA-backed band: $9.90–$29.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$99

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

99.7% (HPLC) reported for one vendor batch (Skye Peptides, batch SV25-06-001, 6 mg); independent aggregate testing across multiple vendors shows purity generally at or above ~98% when identity is confirmed, with quantity/underdosing failures observed at lower-rated vendors.

Independent labs cited for this compound

No FDA drug recalls or market withdrawals listing survodutide (BI 456906) were found in FDA Enforcement Reports or recall databases as of the search date. Survodutide is not an FDA-approved drug; no commercial recall pathway applies. None found.

Buyer red-flag checklist

• Survodutide is not FDA-approved; any retail sale for human use is unlawful (FDA Warning Letter 694608, Dec 10, 2024 explicitly named SURVODUTIDE).
• Investigational dual GCGR/GLP-1R agonist (Phase 3) actively monitored in FDA's GLP-1 enforcement ecosystem; 'For Research Use Only' labeling does not shield vendors making structure/function claims.
• Aggregate independent testing (Finnrick) found at least one vendor with a 'D (Poor)' tentative rating for survodutide, indicating quantity/underdosing risk in the grey-market supply.
• Vendor-published COAs (e.g., Skye Peptides 99.7%) are not independent verification; batch-to-batch variability is expected in unregulated research-peptide supply.
• No USP/NF monograph exists for survodutide; it is not on the FDA 503A or 503B bulks lists, so compounding for human use is not eligible for FDCA exemptions.
• CAS 2805997-46-8 is widely advertised by overseas wholesalers with bulk discounts and Telegram/WhatsApp contact channels — typical grey-market distribution patterns.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Independent aggregate testing (Finnrick Analytics) of survodutide from multiple research-peptide vendors shows variable quantity results: one vendor (Uther) received a tentative 'D (Poor)' rating across 4 samples (no score below 3), indicating quantity/underdosing concerns; another (Qing Li Peptide) received a tentative 'A' across 3 samples; Skye Peptides a tentative 'B' across 4 samples. No single numeric prevalence across the market could be derived from retrieved sources; prevalence is therefore reported as null (not established).

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Small self-selected early-adopter sample
• Gray-market / research-use-only sourcing dominates discussion
• Vendor-affiliated or vendor-loyal posters present
• No controlled dosing; self-reported unverified experiences
• Survodutide not FDA-approved; trial vs gray-market use conflated

Manually researched from reddit— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Dual GLP-1 / glucagon receptor co-agonist (Boehringer Ingelheim / Zealand Pharma) in Phase 3 for obesity and MASH; once-weekly subcutaneous peptide. Approximately 62 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Investigational — not FDA approved; Phase 3 complete for obesity; Phase 3 ongoing for MASH. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet